Study on the usefulness of novel excision repair cross-complementation group-1 (ERCC-1) antibody for predicting the therapeutic effect of FOLFIRINOX therapy for pancreatic cancer

Study on the usefulness of novel excision repair cross-complementation group-1 (ERCC-1) antibody for predicting the therapeutic effect of FOLFIRINOX therapy for pancreatic cancer - Study on the usefulness of novel ERCC-1 antibody for predicting the therapeutic effect of FOLFIRINOX therapy for pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045997

Enrollment

Registered

2021-11-06

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with pancreatic cancer at Nagasaki University Hospital between December 1, 2014 and March 31, 2024 2. Patients with residual specimens who underwent pathological examination at the time of diagnosis

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
1. Ratio of new anti-ERCC-1 antibody and conventional anti-ERCC-1 antibody immunohistochemical staining in surgical specimens 2. Correlation between the expression level of anti-ERCC-1 antibody and ERCC1 RNA in surgical specimens	—

Countries

Japan

Contacts

Public ContactKosuke Takahashi

Nagasaki University Department of Gastroenterology and Hepatology

takapochi0809@gmail.com095-819-7481

Outcome results